The homogenate was centrifuged 800 x g for 10 min and the supernatant (crude cytosol) saved. The nuclear pellet was washed twice with 1 ml of phosphate buffer and the supernatants added to the crude cytosol. This was centrifuged at 105,000 x g in a Beckman 75 Ti rotor and the supernatant (cytosol) used immediately. DNA content in the cytosol pellet which contains mostly microsomes and mitochondria was less than 2% of the total DNA. The nuclear pellet was resuspended in 1 to 3 ml of Tris buffer (10 mM Tris/HCl, pH 8.5, at 4", 1.5 rnM EDTA, 10 rnivr thioglycerol, 10% glycerol) containing 0.6 M KC1 and incubated for 1 h during which time the pellet was resuspended every 15 min. Solubilized proteins were then obtained by centrifugation at 105,000 x g for 30 min. DNA used for calculation of cytoplasmic and nuclear sites was determined from the high speed nuclear pellet by the diphenylamine method of Burton (14) . 
Control of Progesterone
Receptor in Breast Cancer (10, 11). In this study, the number of receptors in untreated cells was equally divided between these two compartments. With increasing doses of estradiol there is progressive depletion of Rc and Rn. At 0.1 nM only 15% of sites remain unfilled and virtually complete depletion occurs at higher doses. Rc does not remain in the cytoplasm in bound form (RcE, 30 incubation; not shown) or in cytoplasmic organelles (0.6 M KC1 extract of high speed pellet). We conclude that Rc is translocated to the nucleus while Rn sites are filled so that all receptor is in the nucleus in bound form (RnE). However, the quantity of RnE measured at different doses is puzzling. After 4-day treatment at the lower doses, although Rc and Rn decrease, there is little accumulation of occupied nuclear receptors (RnE). Instead, total cellular receptors (Rc + Rn + RnE) are progressively lower. At the higher estradiol doses free cytoplasmic and nuclear receptors are entirely depleted but total receptor levels (as RnE) are only 30% of total cell receptor present in controls. There appears to be a limit to the amount of receptor loss, however, so that at higher doses RnE accumulation occurs. One interpretation of these effects is that at low doses all RnE formed from both Rc and Rn are rapidly utilized or processed in a subsequent step to a steady state level that is dependent on dose so that the number of RnE sites that can be processed reach saturation at approximately 0.1 nM estradiol. Excess RnE formed at higher doses remain unprocessed.
The extent of free receptor binding and processing parallels PgR introduction.
Induction is incomplete at low doses if receptor binding and processing are incomplete, reaches a maximum at 0.1 nM when RnE processing is maximal, and is not increased further by accumulation of unprocessed RnE. This suggests that processing is an essential step in induction of a specific protein by estradiol.
Kinetics of ER Processing-The processed receptor levels seen in Fig. 3 were measured 4 days after the start of treatment. If processing is an essential step in genome activation, one would expect it to be an early event in estrogen action. Fig. 4 A and B shows the effect of brief (10 min) or more prolonged (1 to 24 h) estrogen treatment. The dose used, 10 nM, is one at which processing capacity is saturated.
The untreated cells shown in Fig. 44 have 70% of free receptor in the nucleus and 30% in the cytoplasm. After 10 min on estradiol, Rc and Rn are no longer measurable and all cellular receptors appear in the nucleus bound to estradiol. Despite the short incubation time (cells were treated, harvested, and cooled to 4" within 30 min), processing has started as shown by the decrease in total receptors in the estradioltreated group. Panel B shows again that processing is well underway by 1 h so that maximal RnE buildup is not seen. Processing is essentially complete by 5 h, thereafter, RnE is stabilized at the new steady state level (24 h and Fig. 5 ). We do not know whether this is a static state or a dynamic state involving continuous receptor turnover; the extended time course and replenishment studies below show that the cells are capable of new receptor synthesis.
ER Distribution during Replenishment -The compartmen- Each point represents triplicate determinations from four pooled T-75 flasks. talization of ER following 12-day estrogen exposure or withdrawal is shown in Fig. 5 . After estrogen treatment, Rc and Rn disappear, total receptor levels fall approximately 70%, and are found in the nucleus as RnE. Receptor levels then remain unchanged during the entire 12-day course of estrogen treatment.
In cells from which estradiol has subsequently been removed, several effects are seen. The binding of estradiol to Rn (RnE) is remarkably prolonged. Although there is loss of RnE on Days 4 to 12, at least some estrogen always remains bound to nuclear receptor. Thus, restoration of cell ER cannot be explained by loss of estrogen from the nuclear receptor followed by redistribution of the newly emptied sites. Instead, both cytoplasmic receptors (Rc) and nuclear receptors (Rn) are clearly being synthesized de nouo, and this synthesis is reflected in the restoration of total cellular ER. Since hormone withdrawal serves as a trigger of Rn reappearance, it seems unlikely that the nuclear localization of Rn is a result of translocation from the cytoplasm after estrogen binding. Table I summarizes receptor distribution in untreated, role of estradiol and ER in PgR induction is sustained by studies in which the levels of the two receptors are contrasted after treatment with and withdrawal from estradiol (Fig. 6) . Cells on continuous estrogen treatment attain processed ER levels prior to PgR induction. Induction is slow, then stimulated PgR levels are maintained as long as estrogen is present. If estrogen is removed, processing stops and ER are restored, while PgR levels fall to basal values.
The reciprocal relationship between PgR levels and ER processing again suggests that processing is a necessary intermediate step following RnE binding and preceding synthesis of a specific estrogen-regulated protein.
DISCUSSION
We have shown that MCF-7 cells of human breast cancer origin respond to estradiol treatment with increased levels of PgR, as would be predicted from studies of chick oviduct (231, rat uterine PgR priming (24), and cyclic changes in PgR levels observed in the human endometrium (25). Our results clearly show that human breast cells which have undergone malignant transformation can continue to synthesize a specific protein under hormone control. Furthermore, these results lend credence to our hypothesis (5) that the presence of PgR in biopsies of human breast tumors indicates that in situ the tumor was exposed to and was capable of responding to circulating estrogens. Since the tumor, in one instance, has remained hormone responsive, one might suspect that other estrogen-sensitive effects have also been retained. We must emphasize, however, that PgR induction is only one product of estrogen action. The data cannot be construed to mean that other estrogen responses will necessarily be present. We find, for instance, that growth of MCF-7 cells is estrogen-sensitive, but unlike PgR, growth is not estrogendependent. Thus, effects of estrogens on growth and PgR induction might well be dissociated. We find this to be true in some dimethylbenz(a)anthracene tumors as well. Occasional tumors grow in castrate rats so that growth can be considered estrogen autonomous, while tumor PgR levels decline and could, therefore, be considered estrogen dependent (26). Conversely, we would predict that tumors regressing while on high dose estradiol would have elevated PgR levels.
Our studies strongly suggest that estrogen stimulation of PgR involves ER. First, the extent of PgR induction parallels closely both the binding and translocation of Rc and the binding of Rn. Second, PgR induction is correlated with ER processing during estradiol stimulation; when processing ceases PgR levels fall.
The nature of processing is unclear. It may be an active state in which a new equilibrium between degradation and synthesis is achieved (27, 28), or a redistribution of receptor within nuclear binding sites of differing affinities (29) or specificities (30), or sequestration of receptor to sites inaccessible to salt extraction (31, 32). Regardless, our data would suggest that the processing step is saturable, that peak activation occurs when RnE processing is maximal, and that the RnE accumulated in excess of that which is processed may be superfluous. That is, a dose of 0.1 nM estradiol is equal to 10 nM estradiol despite the fact that for the former some Rc 
